MarginsXMarginsX
Home › Markets › Health Care › PROK

ProKidney Corp. (PROK)

PROK trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.04
-0.48% on the day
Market cap
$314.5M
Small cap
Revenue · 2025
$893K
+1075.0% on 2024
Net income · 2025
-$69.0M
-7725.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1850270/000119312526113881/0001193125-26-113881-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPROK on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001850270
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inCayman Islands

Financials · 2025

LineValue
Revenue$893K
Net income-$69.0M
Operating income-$165.0M
Net margin-7725.2%
Operating margin-18477.8%
Revenue growth+1075.0%
Cash$108.5M
Total assets$335.6M
P/E (computed)Net income was not positive
P/S (computed)352.2×

Warning signs

Cash runway
6.4 months
$81.4M cash at September 30, 2026
Share count, 1 year
+0.5%
2025-10-31 to 2026-11-12
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
-$3.0M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These matters raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$81.4M cash; operating cash flow -$38.3M a quarter.Report 2026-09-30
Shares outstanding302,381,712 (2026-11-12); 300,834,379 a year earlier.Cover page 2026-11-12
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-11-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Atlanta, Georgia, United StatesPCAOB Form AP 2026-04-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $3.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$174K-$35.6M-$38.7M$81.4MNo debt tags$775K10-Q 2026-11-12
Q2 2026
2026-06-30
$150K-$28.4M-$40.4M$74.9MNo debt tags$818K10-Q 2026-08-10
Q1 2026
2026-03-31
$226K-$20.0M-$41.7M$101.9MNo debt tags$889K10-Q 2026-05-15
Q4 2025
2025-12-31
$225K-$19.2M-$32.5M$108.5MNo debt tags$893K10-K 2026-03-18
Q3 2025
2025-09-30
$217K-$16.5M-$26.6M$95.3MNo debt tags$744K10-Q 2026-11-12
Q2 2025
2025-06-30
$221K-$16.6M-$31.4M$84.9MNo debt tags$527K10-Q 2026-08-10
Q1 2025
2025-03-31
$230K-$16.7M-$29.6M$97.8MNo debt tags$306K10-Q 2026-05-15
Q4 2024
2024-12-31
$76K-$21.3M-$24.2M$99.1MNo debt tags$76K10-K 2026-03-18

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-12
Latest annual report10-K2026-03-18
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-17

Source: SEC EDGAR submissions feed, 406 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.3%
1 month-33.4%
3 months-25.6%
Year to date-53.3%
1 year-54.2%
From 52-week high-59.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
AUTLAutolus Therapeutics plc American Depositary Share$1.14-2.56%$303.6M
KYTXKyverna Therapeutics Inc.$4.76-5.74%$300.9M
IPSCCentury Therapeutics Inc.$1.64-0.61%$297.8M
TRXBTRex Bio Inc.$10.77-21.21%$295.6M
AGMBAgomAb Therapeutics NV$5.97-6.13%$294.0M
EIKNEikon Therapeutics Inc.$5.38-9.95%$291.8M
SCTXScribe Therapeutics Inc.$15.37-6.05%$291.1M
XFORX4 Pharmaceuticals Inc.$2.83-9.29%$289.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier